These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 9607891

  • 1. Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.
    Zaher TF.
    Int Urol Nephrol; 1998; 30(2):193-6. PubMed ID: 9607891
    [Abstract] [Full Text] [Related]

  • 2. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O, Hanani J, Shalhav A, Vardi Y, Goldwasser B.
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP, Engel RM, Smolev JK, Brendler CB.
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [Abstract] [Full Text] [Related]

  • 8. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.
    Kattan S, Collins JP, Mohr D.
    Urology; 1991 Jun; 37(6):516-8. PubMed ID: 2038782
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R, Asakawa M, Kawashima H, Yoshimura R, Maekawa T, Kashiwara N, Tanaka H, Nishio S.
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An improved vasoactive drug combination for a pharmacological erection program.
    Bennett AH, Carpenter AJ, Barada JH.
    J Urol; 1991 Dec; 146(6):1564-5. PubMed ID: 1719248
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y, Lidgi S, Moskovitz B, Levin RD.
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [Abstract] [Full Text] [Related]

  • 19. Comparison of Alprostadil (Caverject) and a combination of vasoactive drugs as local injections for the treatment of erectile dysfunction.
    Abdallah HM.
    Int Urol Nephrol; 1998 Oct; 30(5):617-20. PubMed ID: 9934808
    [Abstract] [Full Text] [Related]

  • 20. A comparative study with intracavernous injection of prostaglandin E1 versus papaverine for the diagnostic assessment of erectile impotence.
    Wang CJ, Wu CC, Huang CH, Chiang CP.
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Nov; 8(11):585-90. PubMed ID: 1296038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.